What Researchers Did
Researchers conducted a systematic review to assess the efficacy and safety of hyperbaric oxygen treatment (HBOT) for patients with SARS-COV-2 (COVID-19) pneumonia.
What They Found
The review included six publications (one cohort study, five case reports/series) involving 37 hypoxaemic COVID-19 patients treated with HBOT. Among 26 patients whose outcomes were assessed, 24 did not require intubation or mechanical ventilation, and 23 survived, with no serious adverse events reported.
What This Means for Canadian Patients
For Canadian patients with COVID-19, HBOT could potentially offer a low-risk, non-invasive option to reduce the need for mechanical ventilation and improve survival. However, more robust clinical trials are needed to confirm these preliminary findings before widespread implementation.
Canadian Relevance
This systematic review was conducted by Canadian researchers, making its findings directly relevant to healthcare discussions and potential treatment strategies within Canada.
Study Limitations
The primary limitation was the low quality of the included evidence, consisting mainly of case reports and series, with no randomized controlled trials available.